Glucosyl hesperidin lowers serum triglyceride level in hypertriglyceridemic subjects through the improvement of very low-density lipoprotein metabolic abnormality

Journal of Nutritional Science and Vitaminology
Yoshikatsu MiwaMasayoshi Kibata

Abstract

To examine the serum triglyceride (TG)-lowering effect of a soluble hesperidin derivative, glucosyl hesperidin (G-hesperidin), and its mechanisms, we carried out a G-hesperidin administration test in hypertriglyceridemic subjects. G-Hesperidin was administered to the subjects at 500 mg/d for 24 wk. In this study, the subjects were classified into high-TG type (TG > 150 mg/dL), borderline-TG type (TG 110-150 mg/dL) and normal-TG type (TG < 110 mg/dL) on the basis of their initial serum TG values. Among these phenotypes, serum TG level significantly decreased in the high-TG type during the G-hesperidin administration period. It was also observed that elevated values of serum remnant-like particle cholesterol (RLP-C), apolipoprotein (apo) B, apo C-II, apo C-III and apo E occurred in the high-TG type and that these serum levels were significantly reduced by G-hesperidin administration. Moreover, polyacrylamide gel electrophoresis analysis of serum lipoproteins revealed that the very low-density lipoprotein (VLDL)/low-density lipoprotein (LDL) ratio and LDL migration index of the high-TG type were remarkably higher than those of the other phenotypes but that their high values were significantly reduced by the administration. These r...Continue Reading

Citations

May 28, 2013·Journal of the International Society of Sports Nutrition·David Michel de OliveiraThais Borges Cesar
Sep 14, 2006·Journal of Nutritional Science and Vitaminology·Yoshikatsu MiwaMasayoshi Kibata
Sep 16, 2015·Journal of Molecular Recognition : JMR·Verônica Trícoli de SouzaPatricia de Oliveira Carvalho
Jun 9, 2016·Journal of Agricultural and Food Chemistry·Huimin PengXiangliang Yang
Nov 3, 2007·Phytochemistry·Juan Carlos EspínFrancisco A Tomás-Barberán
May 6, 2016·Annual Review of Nutrition·Erin E MulvihillMurray W Huff
Jun 24, 2006·Bioscience, Biotechnology, and Biochemistry·Mika YamadaMasayoshi Kibata
Dec 21, 2012·Current Opinion in Lipidology·Julia M AssiniMurray W Huff
Feb 6, 2020·Molecular Medicine Reports·Yosuke NakazawaHiroomi Tamura
Apr 10, 2019·Oxidative Medicine and Cellular Longevity·Ayman M MahmoudOmnia E Hussein
Jan 23, 2020·Pharmaceuticals·Segewkal H HeruyeCatherine A Opere
Jun 2, 2016·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Aya UmenoYasukazu Yoshida
May 31, 2018·Molecular Medicine Reports·Yosuke NakazawaHiroomi Tamura
Apr 5, 2017·The Journal of Medical Investigation : JMI·Hitomi KobayashiTohru Sakai
Oct 8, 2019·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Babalwa U JackCarmen Pheiffer
Jan 14, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Kokila Vani PerumalHasnah Bahari
Mar 2, 2021·Biological & Pharmaceutical Bulletin·Hiroki YoshidaMasahiko Kurokawa
Jul 13, 2021·Frontiers in Physiology·Naoki NishimuraKeiko Yamamoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.